Boston University

room765 Commonwealth Ave
arrow_backSee all Organisations

  • Total Commitments

    $0

  • Total Disbursements

    $0

  • Total Expenditures

    $30.24 M

  • Total Incoming Funds

    $0

  • Queensland ODA - OctapeptinX (OPX) for XDR Gram-negative infections IATI

    IATI Identifier: US-EIN-04-2103547-Queensland
    • date_range Jul 01, 2020 - Mar 31, 2021
    • autorenew Pipeline/identification (Status)
    Total Budget 1,592,673 USD

  • Avails: The eAST - a rapid, electronic device for direct from positive blood culture AST IATI

    IATI Identifier: US-EIN-04-2103547-US-EIN-04-2103547-Avails
    • date_range Jul 01, 2022 - Jan 31, 2024
    • autorenew Implementation (Status)
    Total Budget 4,295,591 USD

  • Integrated Biotherapeutics -IBT V-02 IATI

    IATI Identifier: US-EIN-04-2103547-Integrated Biotherapeutics
    • date_range Oct 01, 2017 - Aug 31, 2023
    • autorenew Implementation (Status)
    Total Budget 3,537,185 USD

  • GVGH-Sal: 06CARB-X968; A combination vaccine for sustainable prevention of invasive Salmonelloses in sub-Saharan Africa IATI

    IATI Identifier: US-EIN-04-2103547-GSK Bio Sal
    • date_range Oct 01, 2020 - Dec 31, 2024
    • autorenew Implementation (Status)
    Total Budget 607,519 USD

  • BB100 - A Humanized Monoclonal Antibody Targeting multi-Drug Resistant Escherichia coli ST131-O25b IATI

    • date_range Jul 01, 2019 - Sep 30, 2020
    • autorenew Implementation (Status)
    Total Budget 989,142 USD

  • Procarta - PRO-202 IATI

    • date_range Jul 01, 2019
    • autorenew Implementation (Status)
    Total Budget 1,141,350 USD

  • BioVersys - Anti-Virulence Adjunctive Therapy Against Resistant Staphylococus aureus (AVATAR-SA) IATI

    • date_range Nov 01, 2019 - Apr 30, 2021
    • autorenew Implementation (Status)
    Total Budget 1,969,092 USD

  • Lytica - Stapled Antimicrobial Peptides for Gram-negative Infections IATI

    • date_range Oct 01, 2019 - Jun 30, 2021
    • autorenew Implementation (Status)
    Total Budget 1,760,549 USD

  • Lumen - Oral anti-microbial immunotherapy against ETEC and campylobacter IATI

    IATI Identifier: US-EIN-04-2103547-Lumen
    • date_range Aug 01, 2020 - Jul 31, 2023
    • autorenew Implementation (Status)
    Total Budget 1,616,505 USD

  • Amicrobe - Amicidin-Beta IATI

    IATI Identifier: US-EIN-04-2103547-Amicrobe
    • date_range Mar 01, 2019
    • autorenew Implementation (Status)
    Total Budget 4,844,287 USD

  • GangaGen Engineered therapeutic protein antibiotics targeting drug-resistant Enterobacteriaceae IATI

    IATI Identifier: US-EIN-04-2103547-GangaGen
    • date_range Aug 01, 2020 - Jun 30, 2024
    • autorenew Implementation (Status)
    Total Budget 705,726 USD

  • Phico: Pre-clinical and clinical development of intravenous Pseudomonas aeruginosa SASPject technology IATI

    IATI Identifier: US-EIN-04-2103547-Phico
    • date_range Feb 01, 2021 - Apr 30, 2023
    • autorenew Implementation (Status)
    Total Budget 1,736,851 USD

  • Cross-Project Initiative IATI

    • date_range Apr 01, 2021
    • autorenew Implementation (Status)
    Total Budget 648,527 USD

  • Jenner - dmGC_0817560 IATI

    IATI Identifier: US-EIN-04-2103547-Jenner / Oxford
    • date_range Jan 01, 2021 - Aug 31, 2024
    • autorenew Implementation (Status)
    Total Budget 1,402,617 USD

  • HZI CIR - Small molecule inhibitors of α-hemolysin for the treatment of S. aureus lung infections IATI

    IATI Identifier: US-EIN-04-2103547-Helmhltz CIR
    • date_range Oct 01, 2020 - May 31, 2024
    • autorenew Implementation (Status)
    Total Budget 438,824 USD

  • GVGH-GAS: Group A Streptococcus vaccine (06CARB-X0955) IATI

    IATI Identifier: US-EIN-04-2103547-GSK Bio GAS
    • date_range Oct 01, 2020 - Aug 31, 2023
    • autorenew Implementation (Status)
    Total Budget 1,602,606 USD

  • Vaxcyte - Safe Universal Carbohydrate Conjugate GAS Vaccine IATI

    IATI Identifier: US-EIN-04-2103547-Vaxcyte (fmr SutroVax)
    • date_range Jun 01, 2019 - Dec 31, 2023
    • autorenew Implementation (Status)
    Total Budget 3,142,365 USD

  • Visby - Rapid detection of Neisseria Gonorrhea and antimicrobial susceptibility from urogenital samples - 1235 IATI

    IATI Identifier: US-EIN-04-2103547-Visby
    • date_range Jul 01, 2023
    • autorenew Implementation (Status)
    Total Budget 179,539 USD

  • Vaxdyn - KAPAVAX IATI

    IATI Identifier: US-EIN-04-2103547-Vaxdyn
    • date_range Jun 01, 2019 - Aug 30, 2024
    • autorenew Implementation (Status)
    Total Budget 1,083,102 USD

  • University of Melbourne - Novel ionophore combination therapeutic treatment IATI

    IATI Identifier: US-EIN-04-2103547-UMelbourne
    • date_range Sep 01, 2023
    • autorenew Implementation (Status)
    Total Budget 174,524 USD

  • Intravacc - Avacc 12: An Outer Membrane Vesicle vaccine for Neisseria gonorrhoeae IATI

    IATI Identifier: US-EIN-04-2103547-Intravacc
    • date_range Nov 01, 2023
    • autorenew Implementation (Status)
    Total Budget 31,656 USD

  • LimmaTech - Development of a Multivalent Gonococcal Vaccine IATI

    IATI Identifier: US-EIN-04-2103547-LimmaTech-Gonococcus
    • date_range Jul 01, 2023
    • autorenew Implementation (Status)
    Total Budget 216,993 USD

  • Syntiron - Alloy Vaccine: An iron receptor protein vaccine to prevent Enterobacteriaceae infections IATI

    IATI Identifier: US-EIN-04-2103547-Syntiron
    • date_range Jul 01, 2023
    • autorenew Implementation (Status)
    Total Budget 50,774 USD